De-Wei An

Dec 6, 2024 | ebn.bmj.com | De-Wei An |Jan A. Staessen |KU Leuven

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. CardiologyPublic HealthCommentary on: Su D, Yang H, Chen Z, et al.

Oct 22, 2024 | medrxiv.org | EnHeng Cai |De-Wei An |Jin Zhang |Xiaofeng Tang

The authors have declared no competing interest. This project was supported by grants from NRCTM(SH)-2021-05, the National Natural Science Foundation of China (81670213), National Key Program for Basic Research (2009CB521905), Shanghai Municipal Health Bureau Foundation (201640243). The funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Sep 5, 2024 | nature.com | Fang-Fei Wei |Pierpaolo Pellicori |Joao Ferreira |Arantxa González |De-Wei An |Chen Liu | +10 more

AbstractNone of the spironolactone trials in heart failure (HF) assessed the blood pressure (BP) responses to exercise, while conflicting results were reported for exercise capacity. In the HOMAGE trial, 527 patients at increased HF risk were randomized to usual treatment with or without spironolactone (25–50 mg/day). The current substudy included 113 controls and 114 patients assigned spironolactone, who all completed the incremental shuttle walk test at baseline and months 1 and 9.